Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 06-Feb-24 8:18 PM View:  | Rodriguez Raul R CEO, President Director | Rigel Pharmaceuticals, Inc. (RIGL) | 05-Feb-24 | Sale | 30,545 | $1.14 | $34,821.30 | (1%) 2.07M to 2.04M | |
| 06-Feb-24 8:18 PM View: | Schorno Dean L EVP & Chief Financial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 05-Feb-24 | Sale | 7,027 | $1.14 | $8,010.78 | (2%) 409.92K to 402.89K | |
| 06-Feb-24 8:18 PM View: | Santos David A EVP, Chief Commercial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 05-Feb-24 | Sale | 8,918 | $1.14 | $10,166.50 | (2%) 358.01K to 349.09K | |
| 06-Feb-24 8:18 PM View: | Schorno Dean L EVP & Chief Financial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 02-Feb-24 | Sale | 5,601 | $1.13 | $6,326.89 | (1%) 415.52K to 409.92K | |
| 06-Feb-24 8:18 PM View: | Santos David A EVP, Chief Commercial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 02-Feb-24 | Sale | 5,601 | $1.13 | $6,329.13 | (2%) 363.61K to 358.01K | |
| 06-Feb-24 8:18 PM View: | Rodriguez Raul R CEO, President Director | Rigel Pharmaceuticals, Inc. (RIGL) | 02-Feb-24 | Sale | 22,349 | $1.13 | $25,261.10 | (1%) 2.09M to 2.07M | |
| 25-Jan-24 9:17 PM View: | Santos David A EVP, Chief Commercial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 23-Jan-24 | Grant | 209,000 | -- | -- | 135% 154.61K to 363.61K | |
| 25-Jan-24 9:17 PM View: | Rodriguez Raul R CEO, President Director | Rigel Pharmaceuticals, Inc. (RIGL) | 23-Jan-24 | Grant | 400,000 | -- | -- | 24% 1.69M to 2.09M | |
| 25-Jan-24 9:16 PM View: | Schorno Dean L EVP & Chief Financial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 23-Jan-24 | Grant | 209,000 | -- | -- | 101% 206.52K to 415.52K | |
| 25-Jan-24 9:17 PM View: | Furey Raymond J. EVP, GC, CCO & Corp Sec | Rigel Pharmaceuticals, Inc. (RIGL) | 23-Jan-24 | Grant | 209,000 | -- | -- | 4180% 5.0K to 214.0K | |
| 12-Jul-23 6:45 PM View: | Wasman Jane Director | Rigel Pharmaceuticals, Inc. (RIGL) | 26-May-23 | Grant | 25,000 | -- | -- | 50% 50.0K to 75.0K | |
| 12-Jul-23 6:45 PM View: | Kotzin Brian L. Director | Rigel Pharmaceuticals, Inc. (RIGL) | 26-May-23 | Grant | 25,000 | -- | -- | 50% 50.0K to 75.0K | |
| 12-Jul-23 6:45 PM View: | Lapointe Gregg Anthony Director | Rigel Pharmaceuticals, Inc. (RIGL) | 26-May-23 | Grant | 25,000 | -- | -- | 50% 50.0K to 75.0K | |
| 12-Jul-23 6:45 PM View: | Lyons Gary A Director | Rigel Pharmaceuticals, Inc. (RIGL) | 26-May-23 | Grant | 25,000 | -- | -- | 50% 50.0K to 75.0K | |
| 12-Jul-23 6:45 PM View: | Ali-Jackson Kamil Director | Rigel Pharmaceuticals, Inc. (RIGL) | 26-May-23 | Grant | 25,000 | -- | -- | 133% 18.75K to 43.75K | |
| 12-Jul-23 6:45 PM View: | Hannah Alison L. Director | Rigel Pharmaceuticals, Inc. (RIGL) | 26-May-23 | Grant | 25,000 | -- | -- | 80% 31.25K to 56.25K | |
| 12-Jul-23 6:45 PM View: | Moos Walter H Director | Rigel Pharmaceuticals, Inc. (RIGL) | 26-May-23 | Grant | 25,000 | -- | -- | 48% 52.22K to 77.22K | |
| 07-Feb-23 4:30 PM View: | Rodriguez Raul R CEO, President Director | Rigel Pharmaceuticals, Inc. (RIGL) | 06-Feb-23 | Sale | 20,340 | $1.75 | $35,595.00 | (1%) 1.7M to 1.68M | |
| 06-Feb-23 5:40 PM View: | Schorno Dean L EVP & Chief Financial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 02-Feb-23 | Sale | 5,389 | $1.66 | $8,946.28 | (3%) 201.91K to 196.52K | |
| 06-Feb-23 5:40 PM View: | Dummer Wolfgang EVP & CMO | Rigel Pharmaceuticals, Inc. (RIGL) | 02-Feb-23 | Sale | 5,389 | $1.66 | $8,946.28 | (7%) 77.85K to 72.46K | |
| 06-Feb-23 5:41 PM View: | Santos David A EVP, Chief Commercial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 02-Feb-23 | Sale | 5,388 | $1.66 | $8,945.16 | (4%) 150.0K to 144.61K | |
| 30-Jan-23 9:45 PM View: | Schorno Dean L EVP & Chief Financial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 26-Jan-23 | Grant | 63,000 | -- | -- | 45% 138.91K to 201.91K | |
| 07-Feb-23 4:30 PM View: | Rodriguez Raul R CEO, President Director | Rigel Pharmaceuticals, Inc. (RIGL) | 26-Jan-23 | Grant | 300,000 | -- | -- | 21% 1.4M to 1.7M | |
| 30-Jan-23 9:45 PM View: | Santos David A EVP, Chief Commercial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 26-Jan-23 | Grant | 80,000 | -- | -- | 114% 70.0K to 150.0K | |
| 13-Jun-22 4:36 PM View: | Rodriguez Raul R CEO, President Director | Rigel Pharmaceuticals, Inc. (RIGL) | 09-Jun-22 | Private Purchase | 1,000,000 | $0.69 | $688,400.00 | 255% 391.78K to 1.39M | |
| 23-May-22 5:50 PM View: | Lyons Gary A Director | Rigel Pharmaceuticals, Inc. (RIGL) | 20-May-22 | Grant | 25,000 | -- | -- | 100% 25.0K to 50.0K | |
| 23-May-22 5:50 PM View: | Ali-Jackson Kamil Director | Rigel Pharmaceuticals, Inc. (RIGL) | 20-May-22 | Grant | 18,750 | -- | -- | 100% 0 to 18.75K | |
| 23-May-22 5:50 PM View: | Hannah Alison L. Director | Rigel Pharmaceuticals, Inc. (RIGL) | 20-May-22 | Grant | 25,000 | -- | -- | 400% 6.25K to 31.25K | |
| 23-May-22 5:50 PM View: | Moos Walter H Director | Rigel Pharmaceuticals, Inc. (RIGL) | 20-May-22 | Grant | 25,000 | -- | -- | 92% 27.22K to 52.22K | |
| 23-May-22 5:50 PM View: | Wasman Jane Director | Rigel Pharmaceuticals, Inc. (RIGL) | 20-May-22 | Grant | 25,000 | -- | -- | 100% 25.0K to 50.0K | |
| 23-May-22 5:50 PM View: | Kotzin Brian L. Director | Rigel Pharmaceuticals, Inc. (RIGL) | 20-May-22 | Grant | 25,000 | -- | -- | 100% 25.0K to 50.0K | |
| 23-May-22 5:50 PM View: | Lapointe Gregg Anthony Director | Rigel Pharmaceuticals, Inc. (RIGL) | 20-May-22 | Grant | 25,000 | -- | -- | 100% 25.0K to 50.0K | |
| 26-Jan-22 8:45 PM View: | Santos David A EVP, Chief Commercial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 24-Jan-22 | Grant | 50,000 | -- | -- | 500% 10.0K to 60.0K | |
| 26-Jan-22 8:46 PM View: | Dummer Wolfgang EVP & CMO | Rigel Pharmaceuticals, Inc. (RIGL) | 24-Jan-22 | Grant | 50,000 | -- | -- | 280% 17.85K to 67.85K | |
| 26-Jan-22 8:42 PM View: | Vance Dolly EVP Corp. Affairs, G.C., Sect. | Rigel Pharmaceuticals, Inc. (RIGL) | 24-Jan-22 | Grant | 50,000 | -- | -- | 487% 10.26K to 60.26K | |
| 26-Jan-22 8:43 PM View: | Rodriguez Raul R CEO, President Director | Rigel Pharmaceuticals, Inc. (RIGL) | 24-Jan-22 | Grant | 200,000 | -- | -- | 104% 191.78K to 391.78K | |
| 26-Jan-22 8:47 PM View: | Schorno Dean L EVP &Chief Financial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 24-Jan-22 | Grant | 50,000 | -- | -- | 63% 78.91K to 128.91K | |
| 21-May-21 9:11 PM View: | Hannah Alison L. Director | Rigel Pharmaceuticals, Inc. (RIGL) | 19-May-21 | Grant | 6,250 | -- | -- | 100% 0 to 6.25K | |
| 21-May-21 9:03 PM View: | Wasman Jane Director | Rigel Pharmaceuticals, Inc. (RIGL) | 19-May-21 | Grant | 25,000 | -- | -- | 100% 0 to 25.0K | |
| 21-May-21 8:57 PM View: | Katkin Keith Director | Rigel Pharmaceuticals, Inc. (RIGL) | 19-May-21 | Grant | 25,000 | -- | -- | 100% 0 to 25.0K | |
| 21-May-21 8:59 PM View: | Kotzin Brian L. Director | Rigel Pharmaceuticals, Inc. (RIGL) | 19-May-21 | Grant | 25,000 | -- | -- | 100% 0 to 25.0K | |
| 21-May-21 8:55 PM View: | Lapointe Gregg Anthony Director | Rigel Pharmaceuticals, Inc. (RIGL) | 19-May-21 | Grant | 25,000 | -- | -- | 100% 0 to 25.0K | |
| 21-May-21 8:50 PM View: | Lyons Gary A Director | Rigel Pharmaceuticals, Inc. (RIGL) | 19-May-21 | Grant | 25,000 | -- | -- | 100% 0 to 25.0K | |
| 21-May-21 9:09 PM View: | Goodwin Bradford S Director | Rigel Pharmaceuticals, Inc. (RIGL) | 19-May-21 | Grant | 25,000 | -- | -- | 250% 10.0K to 35.0K | |
| 21-May-21 9:06 PM View: | Moos Walter H Director | Rigel Pharmaceuticals, Inc. (RIGL) | 19-May-21 | Grant | 25,000 | -- | -- | 1125% 2.22K to 27.22K | |
| 23-May-19 8:21 PM View: | Schorno Dean L EVP &Chief Financial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 22-May-19 | Market Purchase | 50,000 | $2.13 | $106,544.00 | 100% 0 to 50.0K | 74% |
| 16-Oct-18 6:46 PM View: | Cabatuan Nelson Principal Accounting Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 12-Oct-18 | Market Sale (Planned) | 10,000 | $3.12 | $31,200.00 | (99%) 10.06K to 58 | (19%) |
| 19-Sep-18 6:26 PM View: | Duliege Anne-Marie EVP & Chief Medical Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 17-Sep-18 | Option Exercise | 153,000 | $2.43 | $372,495.00 | 100% 0 to 153.0K | |
| 19-Sep-18 6:26 PM View: | Duliege Anne-Marie EVP & Chief Medical Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 17-Sep-18 | Market Option Sale (Planned) | 153,000 | $3.50 | $535,500.00 | (100%) 153.0K to 0 | (6%) |
| 12-Sep-18 7:48 PM View: | Mayer Eldon C. III EVP & Chief Commercial Officer | Rigel Pharmaceuticals, Inc. (RIGL) | 11-Sep-18 | Market Purchase | 50,000 | $3.23 | $161,340.00 | 30% 165.0K to 215.0K | 15% |
